<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03012100</url>
  </required_header>
  <id_info>
    <org_study_id>RU011501I</org_study_id>
    <secondary_id>NCI-2016-01878</secondary_id>
    <secondary_id>RU011501I</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT03012100</nct_id>
  </id_info>
  <brief_title>Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer</brief_title>
  <official_title>Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academic and Community Cancer Research United</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Academic and Community Cancer Research United</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well multi-epitope folate receptor alpha peptide
      vaccine, sargramostim, and cyclophosphamide work in treating patients with triple negative
      breast cancer. Vaccines made from a person's white blood cells mixed with tumor proteins may
      help the body build an effective immune response to kill tumor cells. Drugs used in
      chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor
      cells, either by killing the cells, by stopping them from dividing, or by stopping them from
      spreading. Giving multi-epitope folate receptor alpha peptide vaccine, sargramostim, and
      cyclophosphamide may work better in treating patients with triple negative breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To show that multi-epitope folate receptor alpha peptide vaccine (folate receptor
      [FR]alpha peptide vaccine) with sargramostim (GM-CSF) adjuvant will prolong the disease-free
      survival (DFS) compared to GM-CSF adjuvant treatment in patients with triple negative breast
      cancer.

      SECONDARY OBJECTIVES:

      I. To compare the safety and tolerability of metronomic cyclophosphamide followed by FRalpha
      peptide vaccine with GM-CSF versus GM-CSF alone.

      TERTIARY OBJECTIVES:

      I. To determine whether high level of antibody and cellular immune response toward the
      FRalpha measured at baseline is a prognostic factor for vaccine immune response and/or cancer
      relapse.

      II. To determine whether the level of tumor expression of FRalpha at baseline is a prognosis
      factor for vaccine immune response and/or cancer relapse.

      OUTLINE: Patients are randomized to 1 of 2 arms.

      ARM I: Patients receive cyclophosphamide orally (PO) twice daily (BID) on days 1-7 and 15-21
      of course 1 only. Starting course 2, patients receive multi-epitope folate receptor alpha
      peptide vaccine with sargramostim intradermally (ID) on day 1. Treatment repeats every 28
      days for courses 2-7 and every 6 months for courses 8-14 in the absence of disease
      progression or unacceptable toxicity.

      ARM II: Patients receive cyclophosphamide as in Arm I. Starting course 2, patients receive
      placebo vaccine with sargramostim ID on day 1. Treatment repeats every 28 days for courses
      2-7 and every 6 months for courses 8-14 in the absence of disease progression or unacceptable
      toxicity.

      After completion of study treatment, patients are followed up every 6 months for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Through study completion (average of 5 years)</time_frame>
    <description>Will be estimated using the method of Kaplan-Meier. Will use the stratified log-rank tests.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FRalpha levels</measure>
    <time_frame>Through study completion (average of 5 years)</time_frame>
    <description>FR alpha levels at baseline will be examined as a prognostic factor in the vaccine immune response. A multivariable Cox proportional hazard model will be used to assess baseline FR alpha levels as a potential prognostic factor for immune response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events 4.0</measure>
    <time_frame>Through study completion (average of 5 years)</time_frame>
    <description>The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed by primary disease site to determine toxicity patterns. Will use the Cochran-Mantel Haenszel chi-squared test with study stratification factors. Will use logistic regression to test differences in proportions while controlling for the known covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Through study completion (average of 5 years)</time_frame>
    <description>Will be estimated using the method of Kaplan-Meier. Will use the stratified log-rank tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine induced FRalpha-specific T cell responses defined as the proportion of patients with at least a 2-fold increase in the number of cells/plasma concentration</measure>
    <time_frame>Through study completion (average of 5 years)</time_frame>
    <description>Will be determined along with its corresponding 95% confidence interval.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Bilateral Breast Carcinoma</condition>
  <condition>Estrogen Receptor Negative</condition>
  <condition>HER2/Neu Negative</condition>
  <condition>Progesterone Receptor Negative</condition>
  <condition>Stage IB Breast Cancer AJCC v7</condition>
  <condition>Stage II Breast Cancer AJCC v6 and v7</condition>
  <condition>Stage IIA Breast Cancer AJCC v6 and v7</condition>
  <condition>Stage IIB Breast Cancer AJCC v6 and v7</condition>
  <condition>Stage III Breast Cancer AJCC v7</condition>
  <condition>Stage IIIA Breast Cancer AJCC v7</condition>
  <condition>Stage IIIB Breast Cancer AJCC v7</condition>
  <condition>Stage IIIC Breast Cancer AJCC v7</condition>
  <condition>Stage IV Breast Cancer AJCC v6 and v7</condition>
  <condition>Triple-Negative Breast Carcinoma</condition>
  <condition>Unilateral Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (FRalpha peptide vaccine, sargramostim)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide PO BID on days 1-7 and 15-21 of course 1 only. Starting course 2, patients receive multi-epitope folate receptor alpha peptide vaccine with sargramostim ID on day 1. Treatment repeats every 28 days for courses 2-7 and every 6 months for courses 8-14 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo, sagramostim)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive cyclophosphamide as in Arm I. Starting course 2, patients receive placebo vaccine with sargramostim ID on day 1. Treatment repeats every 28 days for courses 2-7 and every 6 months for courses 8-14 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (FRalpha peptide vaccine, sargramostim)</arm_group_label>
    <arm_group_label>Arm II (placebo, sagramostim)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (FRalpha peptide vaccine, sargramostim)</arm_group_label>
    <arm_group_label>Arm II (placebo, sagramostim)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multi-epitope Folate Receptor Alpha Peptide Vaccine</intervention_name>
    <description>Given ID</description>
    <arm_group_label>Arm I (FRalpha peptide vaccine, sargramostim)</arm_group_label>
    <other_name>FR Alpha Peptide Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given ID</description>
    <arm_group_label>Arm II (placebo, sagramostim)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sargramostim</intervention_name>
    <description>Given ID</description>
    <arm_group_label>Arm I (FRalpha peptide vaccine, sargramostim)</arm_group_label>
    <arm_group_label>Arm II (placebo, sagramostim)</arm_group_label>
    <other_name>23-L-Leucinecolony-Stimulating Factor 2</other_name>
    <other_name>DRG-0012</other_name>
    <other_name>Leukine</other_name>
    <other_name>Prokine</other_name>
    <other_name>rhu GM-CFS</other_name>
    <other_name>Sagramostim</other_name>
    <other_name>Sargramostatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completely resected unilateral or bilateral primary carcinoma of the breast without
             clinical evidence of disease, negative for estrogen receptor (ER) and progesterone
             receptor (PR) (cut-off for positivity is &gt; 1% positive tumor cells with nuclear
             staining), and negative for HER2 as defined by one of the four situations delineated
             below:

               -  HER2 immunohistochemistry (IHC) expression of 0 or 1+ and in-situ hybridization
                  non-amplified

               -  HER2 IHC expression of 0 or 1+ and in-situ hybridization not done

               -  HER2 IHC expression of 2+ and in-situ hybridization non-amplified

               -  IHC not done and in-situ hybridization non-amplified

               -  Note: central review is not required

          -  Completed planned breast surgeries and any radiation therapy &gt;= 30 days prior to
             randomization

          -  Completed last cycle of chemotherapy (which can be given in the adjuvant and/or
             neoadjuvant setting) &gt;= 60 days but not &gt;= 365 days prior to randomization

          -  Patient has at least one of the following:

               -  Pathologic N1-3

               -  Pathologic T3

               -  Neoadjuvant chemotherapy and did not achieve pathologic response at time of
                  surgery

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1

          -  Absolute neutrophil count (ANC) &gt;= 1500/mm^3

          -  Platelet count &gt;= 75,000/uL

          -  Aspartate transaminase (AST) =&lt; 3 x upper limit of normal (ULN)

          -  Creatinine =&lt; 1.5 x ULN

          -  Urine dipstick proteinuria &lt; 2+ or urine protein/creatinine (UPC) ratio =&lt; 1.0; Note:
             patients discovered to have &gt;= 2+ proteinuria on dipstick urinalysis at baseline
             should undergo a 24-hour urine collection and must demonstrate =&lt; 1 g of protein in 24
             hours

          -  Negative serum pregnancy test done =&lt; 14 days prior to randomization, for women of
             childbearing potential only

          -  Provide informed written consent

          -  Willing to return to enrolling institution for follow-up

          -  Willing to provide tissue and blood samples for correlative research studies

        Exclusion Criteria:

          -  Any of the following:

               -  Pregnant women

               -  Nursing women

               -  Women of childbearing potential who are unwilling to employ adequate
                  contraception

          -  Clinical evidence of local recurrence or distant metastases; Note: all patients must
             have either a positron emission tomography (PET)/computed tomography (CT) or a CT of
             chest, abdomen and pelvis and a bone scan; if one or more of these is concerning for
             distant metastases, follow-up imaging and/or biopsy should be performed to rule out
             distant metastases prior to randomization

          -  Inflammatory breast cancer or tumor with deep adherence or cutaneous invasion

          -  Known hypersensitivity reaction to GM-CSF

          -  History of auto-immune disease per physician discretion

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Prior secondary malignancy &lt; 5 years prior to consent (except non-melanoma skin cancer
             or carcinoma in situ of the uterine cervix) or receiving other specific treatment for
             this cancer (monoclonal antibody, small molecule pathway inhibitor)

          -  Treatment with systemic corticosteroid or immune-modulators =&lt; 30 days prior to
             randomization

          -  Concurrent treatment with other experimental drugs or any other systemic anticancer
             therapy (due to unknown drug-vaccine potential interactions)

          -  Immunocompromised patients and patients known to be human immunodeficiency virus (HIV)
             positive and currently receiving antiretroviral therapy

          -  Prior or concurrent use of trastuzumab
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Ruddy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic and Community Cancer Research United</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Donald W. Northfelt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Alvaro Moreno-Aspitia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Onaidy T Torress</last_name>
      <phone>305-243-3379</phone>
      <email>OTorres@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Carmen J. Calfa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simona Olberkyte</last_name>
      <phone>773-702-4848</phone>
      <email>solberkyte@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Rita Nanda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center NCI Community Oncology Research Program</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine M. Canfield</last_name>
      <phone>217-326-1881</phone>
      <email>christine.canfield@carle.com</email>
    </contact>
    <investigator>
      <last_name>Kendrith M. Rowland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center Jefferson</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Socea A. May</last_name>
      <phone>504-842-2373</phone>
      <email>Socea.may@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>John T. Cole</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Hepp</last_name>
      <phone>617-724-0878</phone>
      <email>etripp@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Steven J. Isakoff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referrals Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Kathryn J. Ruddy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parisa Saifollahi</last_name>
      <phone>703-720-5210</phone>
      <email>Parisa.Saifollahi@inova.org</email>
    </contact>
    <investigator>
      <last_name>Mary J. Wilkinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Maronde</last_name>
      <phone>715-389-7542</phone>
      <email>maronde.brenda@marshfieldresearch.org</email>
    </contact>
    <investigator>
      <last_name>Arlene A. Gayle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2016</study_first_submitted>
  <study_first_submitted_qc>January 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2017</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Unilateral Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

